EGFR and non-small cell lung cancer: implications for surgical practice.
作者信息
Varela Gonzalo, Novoa Nuria M
机构信息
Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain.
Service of Thoracic Surgery, Salamanca University Hospital, Salamanca, Spain.
出版信息
Ann Transl Med. 2020 Sep;8(17):1115. doi: 10.21037/atm.2020.04.47.
Abstract
摘要
相似文献
1
EGFR and non-small cell lung cancer: implications for surgical practice.表皮生长因子受体与非小细胞肺癌：对外科手术实践的影响
Ann Transl Med. 2020 Sep;8(17):1115. doi: 10.21037/atm.2020.04.47.
2
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.中国非小细胞肺癌中靶向下一代测序鉴定的驱动基因的基因组特征。
Oncologist. 2019 Nov;24(11):e1070-e1081. doi: 10.1634/theoncologist.2018-0572. Epub 2019 Mar 22.
3
Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer.小活检标本与手术标本在检测非小细胞肺癌中表皮生长因子受体（EGFR）突变和棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶（EML4-ALK）方面的比较
Oncotarget. 2016 Sep 13;7(37):59049-59057. doi: 10.18632/oncotarget.10011.
4
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.了解非小细胞肺癌中表皮生长因子受体的耐药机制及疾病进展时活检的作用。
Oncologist. 2017 Jan;22(1):3-11. doi: 10.1634/theoncologist.2016-0285. Epub 2016 Nov 7.
5
Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.脑和肺部病变手术切除后序贯 EGFR-TKIs 治疗，可使 EGFR 突变型非小细胞肺癌伴孤立性脑转移患者获得长期生存。
World J Surg Oncol. 2017 Oct 16;15(1):184. doi: 10.1186/s12957-017-1252-y.
6
Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer.致癌状态对切除的非小细胞肺癌复发模式的影响。
Jpn J Clin Oncol. 2016 Oct;46(10):928-934. doi: 10.1093/jjco/hyw094. Epub 2016 Jul 11.
7
Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer.奥希替尼治疗新诊断的、晚期 EGFR 突变阳性非小细胞肺癌的成本效益。
Oncologist. 2019 Mar;24(3):349-357. doi: 10.1634/theoncologist.2018-0150. Epub 2018 Sep 26.
8
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for -Positive Non-Small Cell Lung Cancer (MOST Study).从诊断-治疗途径到真实世界数据：一项关于初治 -阳性非小细胞肺癌的多中心前瞻性研究（MOST 研究）。
Oncologist. 2019 Jun;24(6):e318-e326. doi: 10.1634/theoncologist.2018-0712. Epub 2019 Mar 7.
9
Uncommon EGFR Mutations in Non-Small Cell Lung Cancer and Their Impact on the Treatment.非小细胞肺癌中的罕见表皮生长因子受体（EGFR）突变及其对治疗的影响
Klin Onkol. 2019 Fall;32(Supplementum 3):6-12. doi: 10.14735/amko20193S6.
10
Association of CD8 T cell apoptosis and EGFR mutation in non-small lung cancer patients.非小细胞肺癌患者 CD8 T 细胞凋亡与 EGFR 突变的相关性。
Thorac Cancer. 2020 Aug;11(8):2130-2136. doi: 10.1111/1759-7714.13504. Epub 2020 Jun 4.
本文引用的文献
1
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.新辅助 PD-1 抑制剂（信迪利单抗）治疗 NSCLC。
J Thorac Oncol. 2020 May;15(5):816-826. doi: 10.1016/j.jtho.2020.01.017. Epub 2020 Feb 6.
2
Surgical outcomes of stage IV non-small cell lung cancer: a single-center experience.IV期非小细胞肺癌的手术治疗结果：单中心经验
J Thorac Dis. 2019 Dec;11(12):5463-5473. doi: 10.21037/jtd.2019.11.30.
3
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).转化医学学会关于表皮生长因子受体（EGFR）突变型肺癌术后管理的共识（2019年版）
Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14.
4
Membrane receptor activation mechanisms and transmembrane peptide tools to elucidate them.膜受体激活机制和跨膜肽工具来阐明它们。
J Biol Chem. 2020 Feb 14;295(7):1792-1814. doi: 10.1074/jbc.REV119.009457. Epub 2019 Dec 25.
5
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.NCCN 指南解读：非小细胞肺癌，第 1.2020 版。
J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472. doi: 10.6004/jnccn.2019.0059.
6
[Guidelines for the macroscopic management of surgically resected lung carcinoma].[手术切除肺癌的宏观管理指南]
Ann Pathol. 2019 Dec;39(6):425-432. doi: 10.1016/j.annpat.2019.05.008. Epub 2019 Oct 8.
7
A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.辅助 EGFR-TKIs 治疗可切除非小细胞肺癌的荟萃分析。
Lung Cancer. 2019 Nov;137:7-13. doi: 10.1016/j.lungcan.2019.08.002. Epub 2019 Aug 5.
8
Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence.辅助化疗增加非小细胞肺癌复发中程序性死亡配体 1（PD-L1）的表达。
Clin Lung Cancer. 2019 Sep;20(5):391-396. doi: 10.1016/j.cllc.2019.05.013. Epub 2019 Jun 5.
9
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.寡转移非小细胞肺癌患者的局部巩固治疗与维持治疗或观察：多机构、Ⅱ期、随机研究的长期结果。
J Clin Oncol. 2019 Jun 20;37(18):1558-1565. doi: 10.1200/JCO.19.00201. Epub 2019 May 8.
10
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer.程序性死亡配体1在早期可切除非小细胞肺癌中的表达
Oncotarget. 2019 Jan 15;10(5):561-572. doi: 10.18632/oncotarget.26529.
Zotero 插件